BioRestorative Therapies ...

NASDAQ: BRTX · Real-Time Price · USD
1.51
0.01 (0.65%)
At close: Aug 15, 2025, 3:50 PM
1.52
0.66%
After-hours: Aug 15, 2025, 04:00 PM EDT

BioRestorative Therapies Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
303.3K 25K 43.3K 233.6K 89.1K 35K 19.3K 30.7K 64.5K 31.3K 3.7K 29K 71.1K 16K 5K 8K 15K 18K
Cost of Revenue
8.73K 2.91K 3.34K 18.24K 6.49K 42.71K 42.71K -15.88K 70.54K 68.36K 104.88K 60.24K 60.53K 55.02K 50.56K n/a n/a n/a
Gross Profit
294.57K 22.09K 39.96K 215.36K 82.61K -7.71K -23.41K 30.7K -6.04K -37.06K -101.18K -31.24K 10.57K -39.02K -45.56K 8K 15K 18K
Operating Income
-3.31M -4.81M -2.69M -2.29M -2.47M -4.11M -3.22M -3.1M -3.12M -5.78M -4.68M -4.61M -4.63M -5.05M -4.01M -3.69M -3.56M -15.05M
Interest Income
73.92K 99.97K 118.99K 158.55K 175.94K 162.6K 376.22K 61.67K 96.19K 18.22K 116.11K n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-2.66M -5.34M -1.64M -1.09M -4.03M -2.22M 1.17M 4.77M -2.98M -5.68M -4.35M -4.66M -4.68M -4.82M -20.4M -4.18M -4.06M -15.65M
Net Income
-2.66M -5.34M -1.64M -1.09M -4.03M -2.22M 1.17M 4.77M -2.98M -5.61M -3.82M -4.7M -4.72M -4.58M -20.4M -4.18M -4.06M -15.65M
Selling & General & Admin
1.37M 3.12M 1.07M 1.18M 1.26M 3.04M 2.52M 2.33M 2.21M 4.3M 4.01M 3.65M 3.62M 4.29M 3.85M 3.46M 3.41M 14.91M
Research & Development
2.23M 1.71M 1.66M 1.32M 1.29M 1.06M 680.63K 809.82K 967.89K 1.51M 673.62K 989.17K 1.08M 775.34K 165.5K 237.41K 160.9K 165.25K
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a 39.81K 76.66K -93.86K -17.28K 35.45K -16.65K 74.99K n/a 1.65K 8.39K
Operating Expenses
3.6M 4.83M 2.73M 2.5M 2.55M 4.1M 3.2M 3.14M 3.18M 5.81M 4.59M 4.64M 4.7M 5.05M 4.01M 3.7M 3.57M 15.07M
Interest Expense
n/a n/a n/a n/a n/a n/a 176.07K n/a n/a n/a n/a 28.84K 46.61K 29.01K 213.81K 495.55K 507.33K 598.67K
Selling & Marketing Expenses
n/a n/a 173.06K n/a n/a -42.71K -706 n/a n/a n/a n/a n/a 245.00 469.00 3.17K 300.00 6.22K 2.6K
Cost & Expenses
3.61M 4.83M 2.73M 2.52M 2.56M 4.14M 3.24M 3.14M 3.18M 5.81M 4.59M 4.64M 4.7M 5.05M 4.01M 3.7M 3.57M 15.07M
Income Tax Expense
n/a n/a n/a n/a n/a -3 -3 n/a n/a -76.66K -525.38K 46.13K 46.61K -237.64K n/a -29.01K n/a -4.83K
Shares Outstanding (Basic)
8.74M 8.36M 7.76M 8.12M 8.12M 6.67M 4.71M 4.57M 3.89M 3.72M 3.67M 3.64M 3.64M 3.52M 872.21K 838.69K 795.88K 793.98K
Shares Outstanding (Diluted)
8.74M 8.36M 7.76M 8.12M 8.12M 6.67M 4.71M 4.57M 3.89M 3.72M 3.67M 3.64M 3.64M 3.52M 872.21K 872.21K 836.94K 793.98K
EPS (Basic)
-0.3 -0.64 -0.21 -0.13 -0.5 -0.33 0.25 1.04 -0.77 -1.51 -1.04 -1.29 -1.3 -1.3 -23.39 -4.99 -5.1 -19.72
EPS (Diluted)
-0.3 -0.64 -0.21 -0.13 -0.5 -0.33 0.25 1.04 -0.77 -1.51 -1.04 -1.29 -1.3 -1.3 -23.39 -4.8 -4.85 -19.72
EBITDA
-3.31M -4.81M -2.64M -2.24M -2.42M -4.07M -3.18M 1.74M -3.08M -5.74M -4.8M -4.58M -4.6M -5.03M -20.14M -3.67M -3.53M -15.03M
EBIT
-2.66M -4.81M -2.69M -2.29M -2.47M -4.11M -3.22M 4.77M -3.12M -5.78M -4.82M -4.61M -4.63M -5.05M -20.19M -3.69M -3.56M -15.05M
Depreciation & Amortization
n/a 51.78K 50.37K 48.27K 47.7K 42.71K 42.71K 42.15K 70.54K 68.36K 104.88K 60.24K 60.53K 55.02K 50.56K 50.59K 75.02K 29.04K